CIN: L15142RJ1991PLC006353
SARDA PROTEINS LTD.

Date: 14th February 2026

To,
The Corporate Relationship Department
The Bombay Stock Exchange Limited,
P. J. Towers, Dalal Street, Fort,
Mumbai – 400 001

Subject: Outcome of Board Meeting – Results
OURSELVES: Scrip Code: 519242 ISIN: INE995U01011

Dear Sir/Madam,

Please note that the Board of Directors of the Company in their meeting held today, Saturday, 14th February 2026 at 2.30 pm have considered and approved the unaudited financial results of the Company for the quarter and nine months ended on 31st December 2025. The Board Meeting was concluded at 3.15 pm.

We herewith submit the unaudited financial results along with the Limited Review Report issued by the Statutory Auditors of the Company for the quarter and nine months ended on 31st December 2025.

Kindly take note of the same.

With regards
For, Sarda Proteins Limited
Savaliya Khilan Hareshbhai
Digitally signed by Savaliya Khilan Hareshbhai
Date: 2026.02.14 15:09:49 +05'30'
Khilan Savaliya
Director
DIN: 08790209

Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)
Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)
Contact No.: +91-7737822222; **E Mail:** sardaproteins@yahoo.com; **Web:** www.sardaproteins.com

SARDA PROTEINS LTD

CIN: L15142RJ1991PLC006353

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)

EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 31st DECEMBER, 2025

Rs.in Lakhs

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I.	Revenue from operations	25.00	430.38	2,405.10	1,550.84	2,419.10	2,419.10
II.	Other Income	-	10.54	0.10	10.54	0.10	0.06
III.	**Total Revenue (I+II)**	**25.00**	**440.92**	**2,405.20**	**1,561.38**	**2,419.20**	**2,419.17**
IV.	Expenses:						
	Cost of Material Consumed	-	-	-	-	-	-
	Purchase of Stock -in- Trade	32.17	387.12	2,391.10	1,547.83	2,391.10	2,391.07
	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)	-	-	-	-	-	-
	Employee Benefit Expenses	0.53	0.75	1.30	2.53	6.60	8.94
	Finance Cost	-	-	-	-	-	-
	Depreciation and Amoritsation Expenses	-	-	-	0.05	-	-
	Other expenses	4.11	12.59	3.10	31.66	9.30	17.15
	Total Expenses (IV)	**36.80**	**400.45**	**2,395.50**	**1,582.07**	**2,407.00**	**2,417.16**
V.	Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	(11.81)	40.46	9.70	(20.69)	12.20	2.02
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit/(Loss) before Extraordinary Items and Tax (V-VI)	**(11.81)**	**40.46**	**9.70**	**(20.69)**	**12.20**	**2.02**
VIII.	Extraordinary Items	-	-	-	-	-	-
IX.	Profit/(Loss) before Tax (V-VI)	**(11.81)**	**40.46**	**9.70**	**(20.69)**	**12.20**	**2.02**
X.	Tax Expense:						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	-	-	-	-	-	(1.51)
XI.	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	**(11.81)**	**40.46**	**9.70**	**(20.69)**	**12.20**	**0.51**
XII.	Profit/(Loss) from Discontinued Operations	-	-	-	-	-	-
XIII.	Tax Expenses of Discontinued Operations	-	-	-	-	-	-
XIV.	Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-	-	-
XV.	Profit/(Loss) for the period (IX+XII)	**(11.81)**	**40.46**	**9.70**	**(20.69)**	**12.20**	**0.51**
XVI.	Other Comprehensive Income						
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XVII.	**Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other comprehensive income for the period)**	**(11.81)**	**40.46**	**9.70**	**(20.69)**	**12.20**	**0.51**
	Paid up Equity No. of Share Capital (Face Value of the Share-Rs. 10 Per Share)	17.26	17.26	17.26	17.26	17.26	17.26
XVIII	Earnings per Equity Share						
	(1) Basic	(0.68)	2.34	0.56	(1.20)	0.71	0.03
	(2) Diluted	(0.68)	2.34	0.56	(1.20)	0.71	0.03

Notes:

1. The above results were approved by Audit Committee in their meeting held on 14th Feb 2026 and by Board of Directors in their meeting held on 14th Feb 2026.
2. Segment Results as per AS is not applicable as dealing in only one segment i.e. "Renewable Energy Sector Solar Cell Products".
3. No Investor Complaints were received during the quarter ended 31-Dec-2025 nor any pending as on 01-01-2026.
4. Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period.

On behalf of the Board
For, SARDA PROTEINS LTD

SARDA PROTEINS LIMITED RAJASTHAN

Chirag Thummar
Managing Director
DIN: 10640822

Independent Auditor's Review Report on the Unaudited Standalone Financial Results of Sarda Proteins Limited for the Quarter ended on December, 31, 2025 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Sarda Proteins Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Sarda Proteins Limited (the "Company") for the quarter ended December 31, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for the financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian

Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, A H Mandaliya & Associates
CHARTERED ACCOUNTANTS
FRN: 146705W

HIREN J MANDALIYA
Digitally signed by HIREN J MANDALIYA
Date: 2026.02.14 15:10:01 +05'30'

(Hiren J. Mandaliya)
Partner
Mem. No. :- 140193
UDIN :- 26140193TEFJNT9171

Date :- 14.02.2026
Place :- Ahmedabad